Intranasal gonadotropin-releasing hormone agonist (GnRHa) for luteal-phase support following GnRHa triggering, a novel approach to avoid ovarian hyperstimulation syndrome in high responders
| Autor: | Nurit Carmon, Liron Sheena, Yeela Omer, Daphne Karfunkel-Doron, Yossi Mizrachi, Itai Bar-Hava, Gila Ben-David |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Adult
Ovulation medicine.medical_specialty Menotropins Pregnancy Rate medicine.drug_class media_common.quotation_subject medicine.medical_treatment Ovarian hyperstimulation syndrome Oocyte Retrieval Fertilization in Vitro Luteal phase Drug Administration Schedule Gonadotropin-Releasing Hormone 03 medical and health sciences Nafarelin Ovarian Hyperstimulation Syndrome 0302 clinical medicine Hormone Antagonists Ovulation Induction Pregnancy Risk Factors Gonadotropin-releasing hormone agonist Medicine Humans 030212 general & internal medicine Luteal support Administration Intranasal media_common Retrospective Studies Gynecology 030219 obstetrics & reproductive medicine business.industry Obstetrics and Gynecology Fertility Agents Female medicine.disease Embryo Transfer Embryo transfer Recombinant Proteins Treatment Outcome Reproductive Medicine Infertility Ovulation induction Female Follicle Stimulating Hormone Human business medicine.drug |
| Zdroj: | Fertility and sterility. 106(2) |
| ISSN: | 1556-5653 |
| Popis: | Objective To study whether intranasal GnRH agonist (GnRHa) can be effectively used for luteal support in high-responder patients undergoing fresh-embryo transfer after ovulation induction with the use of GnRHa. Design Retrospective cohort study. Setting Private fertility clinic. Patient(s) Forty-six high-responder patients were administered a GnRHa ovulation trigger to avoid ovarian hyperstimulation syndrome (OHSS), followed by 2 weeks of daily intranasal GnRHa (nafarelin) for luteal-phase support. No additional progesterone supplementation was administrated. Intervention(s) Intranasal GnRHa for luteal-phase support. Main Outcome Measure(s) The primary outcome was ongoing clinical pregnancy rate. Result(s) High median progesterone levels were measured at midluteal phase and on the day of the first positive pregnancy test (190 nmol/L on both measures). We obtained 24 (52.1%) ongoing clinical pregnancies. None of the patients developed OHSS. Conclusion(s) Intranasal GnRHa is effective in achieving luteal-phase support in high-responder patients triggered with GnRHa and avoiding OHSS. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|